Growing European Pharmaceutical Organization Signs Agreement with eResearchTechnology for Cardiac Safety Monitoring and Informat
20 December 2003 - 12:57AM
PR Newswire (US)
Growing European Pharmaceutical Organization Signs Agreement with
eResearchTechnology for Cardiac Safety Monitoring and Information
Distribution Services Award Totals Approximately $1.5 Million for
Thorough Phase I ECG Study PHILADELPHIA, Dec. 19
/PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT) , a
leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has
received an agreement for approximately $1.5 million in cardiac
safety monitoring and services from a growing European-based
pharmaceutical organization for one of its drug candidates in
clinical development. The agreement covers an extensive Phase I
study for which eRT is providing comprehensive support including
the provision, training and ongoing assistance required for
effective use of digital 12-lead ECG equipment designed to
facilitate recording of cardiac safety data that is subsequently
provided to eRT for analysis. eRT will work closely with a leading
CRO on this study and will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT workflow enabled data handling technology, the
first solution in production that was designed explicitly to meet
emerging international regulatory guidance and technical standards.
The study will commence in Q1 2004 and is targeted for completion
over a 90-day period. "The award signifies eRT's increasing
momentum as a provider of services for Thorough Phase I ECG studies
to emerging market participants, as well as traditional Big
Pharma," said Scott Grisanti, senior vice president of business
development and chief marketing officer at eRT. "Further, the
agreement illustrates the international drug development
community's response to emergence of the Global ECG Regulatory
Imperative and the associated best practice for conduct of Thorough
Phase I ECG studies." Based in Philadelphia, PA,
eResearchTechnology, Inc. (http://www.ert.com/) is a provider of
technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis. The company is a
market leader in providing centralized core-diagnostic
electrocardiographic (ECG) technology and services to evaluate
cardiac safety in clinical development. The company is also a
leader in providing technology and services to streamline the
clinical trials process by enabling its customers to automate the
collection, analysis, and distribution of clinical data in all
phases of clinical development. Statements included in this release
may constitute forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the
company's ability to obtain new contracts and accurately estimate
net revenues due to variability in size, scope and duration of
projects, and internal issues in the sponsoring client. As a
result, actual results may differ materially from any financial
outlooks stated herein. Further information on potential factors
that could affect the company's financial results can be found in
the company's Reports on Forms 10-K and 10-Q filed with the
Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-760-487-1137, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles